Savara, Inc. (SVRA)

[DIVEROTC1]

Think so?

[stockyupydowny]

SO buy them? Hold them and watch as it grows - the PPS should be around .75 for break even on MSTVW

[DIVEROTC1]

I only wanna buy the warrants

[stockyupydowny]

Could mean you listened to the wrong people? Or need to do the DD - this one was alerted at.012 and even under that - .20 was already established on speculation and now we ha e events coming up - your here for a reason, hope that’s to make money.

[DIVEROTC1]

You don’t know that for sure. If I had a dollar for every time someone on ihub said that, i wouldn’t have to play pennies.

[tymerz]

I have only been playing the warrants here. Had to throw in SVRA so the board mods don't get upset lol. See ya at the top!

[CHIEF-RISES-ABOVE]

i agree on both accounts, loving the warrants though lol

svra

[tymerz]

I told the panic sellers this was a long play back in January, they didn't listen. Warrant plays are a different beast in the OTC, not your typical OTC ticker. Hope you do well here my friend, this is going way up and so is SVRA.

[stockyupydowny]

No worries, the main focus here is that these warrants are going very undervalued and will be growing at an exponential rate as we progress towards eom. No chasing required, simple buy and hold for some great returns. GL.

[CHIEF-RISES-ABOVE]

count me in here TYMERZ

SVRA

[tymerz]

Read that post wrong, I will admit my bad.

GL!

[stockyupydowny]

That is true except what your commenting on the post about the daily sales for that day - Not the ratio - details friend

[tymerz]

GLTA. I read that post wrong. I will admit, my bad.

[RetroSpect]

$MSTVW free money. Loading every one that I can

[jonnyvs]

970 k pre market buy at 10.30.

[gobluetrader]

Yeah and I will almost get the warrants I own they push it to the exercise price before the expiration date. I agree with the valuation you have given for MSTVW.

[AKAPAK]

Nothing against what you are saying but in full disclosure:

As such, the Warrant Agent Agreement dated November 6, 2014 (original CUSIP 576314132), where the original terms were 22,011,265 warrants for 22,011,265 shares of common stock (1:1), has been adjusted for the 70:1 RSS, resulting in 314,446 warrants for 314,446 shares of common stock, with an exercise price of $52.50 ($.75 x 70), and issued a new CUSIP number: 805111127. The November 12, 2019 expiry date remains unchanged.

Got a ways to go before they are in the money, with a limited time to get there.

Got the above info from company IR.

[stockyupydowny]

$MSTVW: warrants for SVRA - 4 to 1 buys to sell today - another green day - this has some serious potential to move up and fast

[swimmer100]

Interesting action last few days.

SVRA.

[gobluetrader]

The warrants for this are MSTVW, SUPER LOW FLOAT. And if SVRA breaks $10.00 they will go....

[makinezmoney]

$MSTVW: Savara Warrants on the MOVE now


Hitting $0.0129



Could retest January's $0.19 at this rate very very soon.



GO $MSTVW

[Heizenberger]

https://twitter.com/nunnofit/status/1084821610538758144

[Heather Connors]

stock mad shady

[Heather Connors]

stock mad shady

[kpisme]

What a POS stock!

[pray]

Thanks ... thinking of adding but my luck from this in past is I add and a offering comes up.

[lux1]

I can't see anything of relevant before Q3. We float around 10 for a while.
Just my opinion.

[pray]

Do you think to finance tests long term an offering will be in place this quarter?

[chrislal]

https://www.nasdaq.com/article/savara--aironite-fails-to-meet-primary-endpoint-in-indie-phase-2-study-20180311-00015

[Moonlazer]

All I needed to see:

https://www.google.com/amp/s/stocknewstimes.com/2018/03/06/sectoral-asset-management-inc-invests-2-37-million-in-savara-inc-svra-stock.html/amp

[lux1]

Aironite P2 data soon.
Top Line Results From Aironite Phase 2 Clinical Trial for the Treatment of HFpEF to Be Presented at American College of Cardiology 67th Annual Scientific Sessions & Expo on March 11th.


Heart Failure with preserved ejection fraction is an important disease with poor drug options, it is a market of several billion $


http://savarapharma.com/investors/press-releases/release/?id=2332998

[lux1]

Could Molgradex help in pneumonia and lethal influenza?


Some studies are extremely interesting

https://www.ncbi.nlm.nih.gov/pubmed/21474645

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4414562/

[lux1]

last PR about molgradex , 2 case reports
"Both of our patients had a long history of M. abscessus infection that we had not been successful in treating, and both were experiencing a decline in their clinical condition, but when started on inhaled GM-CSF treatment, both demonstrated rapid microbiological response and clinical improvement."

The PR gives us insight that also other lung infections could be treated with Molgarex especially in combo with antibiotics.

http://savarapharma.com/investors/press-releases/release/?id=2330507


Target $35+

[lux1]

2018 year of trials and results.

P3 Molgradex in PAP ends in Q1 and results in Q4.
P3 Aerovanc in MRSA in Cystic Fibrosis continues.
P2 Molgradex in antibiotic-resistant NTM lung infection starts in Q1
P2 Aironite in Heart Failure pEF results Q1-Q2.
P2 Aironite in Heart Failure continues.
P2 Aironite in Cystic Fibrosis and P. aeruginosa infection results in Q1

if Aironite will show effectiveness as expected the target price can easily double due to very large market of heart failure.

[fl89808]

On November 28, 2017, Savara Inc. (“Savara”) entered into Amendment No. 1, effective September 30, 2017, to the Research Program Award Letter Agreement between Savara and Cystic Fibrosis Foundation Therapeutics, Inc. (“CFFT”) dated September 30, 2013 (as amended, the “Award Agreement”), pursuant to which the amount of the development award available to Savara was increased by $5,000,000 to an aggregate of $6,700,000. CFFT is the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation, and the award is available to support the continued development of Savara’s AeroVanc program. The award can be drawn down by Savara as needed upon the achievement of certain milestones set forth in the Award Agreement.

[fl89808]

BARCHART.COM 100% BUY
Resistance at $11.05

[lux1]

Savara CC extremely positive , CEO Neville is doing a very good job with this Company,he was even able to sell the failed Mast's drug Vepoloxamer for royalties!
Cash, good trials progress and new prescriptions only in 6 months.

https://seekingalpha.com/article/4122680-savaras-svra-ceo-rob-neville-q3-2017-results-earnings-call-transcript?page=1

[MiguelHammond10]

all major players saying this is set for mid 20’s

[fl89808]

Savara Announces Start of Pivotal Phase III AVAIL Study of AeroVanc
[Marketwired]
MarketwiredSeptember 26, 2017

AUSTIN, TX --(Marketwired - September 26, 2017) - Savara, Inc. (SVRA), a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases, today announced the initiation of the AVAIL study, a Phase III, randomized, double-blind, placebo-controlled study of AeroVanc (vancomycin hydrochloride inhalation powder) for the treatment of persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection in individuals living with cystic fibrosis (CF).

[fl89808]

Savara Reports Completion of Enrollment in Phase 2 Clinical Trial of Aironite for the Treatment of HFpEF
October 18, 2017) - Savara, Inc. (SVRA), a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases, today reported that patient enrollment is now complete in a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical trial of Aironite, a sodium nitrite solution for inhalation via nebulization, in patients with heart failure with preserved ejection fraction (HFpEF). The 100-patient study, known as the Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF (INDIE-HFpEF) study, is sponsored by Duke Clinical Research Institute (DCRI) as the Coordinating Center for the Heart Failure Clinical Research Network (HFN) and is being conducted at various clinical centers that are part of the HFN. Savara expects that top-line results from the INDIE-HFpEF study will be available in the first half of 2018.

[wallstreetbuyer]

"Secondary offering lockup expirations: Finjan (NASDAQ:FNJN), Bluebird Bio (NASDAQ:BLUE), Hamilton Lane (NASDAQ:HLNE) on August 28; Snap (NYSE:SNAP) on August 29; Savara (NASDAQ:SVRA) and TransUnion (NYSE:TRU) on August 31; "
https://seekingalpha.com/news/3291959-stocks-watch-next-week

[wallstreetbuyer]

"I've been an investor in this Company for 5 years. The CEO is fantastic,"
The CEO is fantastic because.........?

[pray]

Just wished he would update investors as promised when took on this company. Seems like former CEO Cully twin brother. No updates for weeks and slow bleeding.

[LiquidAdventure]

I've been an investor in this Company for 5 years. The CEO is fantastic, his team is outstanding and I think there is much upside. They now have 3 drugs in their pipeline and if any one of them hits, stockholders will be rewarded. And they have enough cash to get them through their next clinical trial.

[b1d]

What's everyone thinking about the future for this company at the moment?

[williamssc]

Aironite Significantly Lowered Pulmonary Artery Pressures and Significantly Increased Pulmonary Arterial Compliance.

"These additional results build upon prior interim data published last year in the Journal of Clinical Investigation, and demonstrate that Aironite can significantly improve cardiopulmonary hemodynamics in HFpEF as well as Group 3 PH patients, both clinical conditions which are inadequately treated by currently approved medicinal treatments," stated Taneli Jouhikainen, M.D., Ph.D., Chief Operating Officer of Savara.

This could be huge folks.

https://finance.yahoo.com/news/positive-interim-results-aironite-phase-120000315.html

[Masala]

Saved by a press release

[b1d]

Down we go huh...

[pray]

Emmaus Life Sciences was able to pass Sickle Cell Tests ... wonder if worthless Cully sold them failed test. Knew it was possible with proper leadership, which proves Cully knew nothing of how to run proper testing.

http://www.emmausmedical.com/Article.aspx?seo=141&l=EN&g=25

[Masala]

Down we go maybe we'll test new lows lockup period we'll be over to hold or to sell?